BrainStorm Cell Therapeutics Inc.
Tel Aviv
417 articles with BrainStorm Cell Therapeutics Inc.
-
BrainStorm to Announce Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update
3/21/2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the fourth quarter and year ended December 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time,
-
BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study
1/10/2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that BCLI will donate biospecimens from NurOwn's placebo-controlled Phase 3 ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) biorepository for use by the research community.
-
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023
1/5/2023
BrainStorm Cell Therapeutics Inc. today announced that Chaim Lebovits , President and CEO, and Stacy Lindborg, Co-CEO, will jointly present a corporate and clinical overview at 10:30 a.m. PT on Monday, Jan. 9 at Biotech Showcase™ 2023.
-
BrainStorm Cell Therapeutics appoints a new co-CEO as it prepares for a January 11th Type A meeting for ALS hopeful NurOwn.
-
BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer
1/4/2023
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced the promotion of Dr. Stacy Lindborg to the role of Co-Chief Executive Officer.
-
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn®
12/27/2022
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the U.S. Food and Drug Administration has granted a Type A meeting to discuss the contents of a refusal to file letter previously issued regarding the company's New Biologics License Application for NurOwn® for the treatment of ALS.
-
BrainStorm Cell Therapeutics Submits Type A Meeting Request to U.S. Food and Drug Administration
12/12/2022
BrainStorm Cell Therapeutics Inc. today announced that the company has submitted a Type A Meeting Request to the U.S. Food and Drug Administration (FDA) to discuss the contents of a refusal to file letter previously issued by the FDA regarding the company's New Biologics License Application (BLA) for NurOwn® for the treatment of ALS.
-
Stevens Nation Responds to FDA's Refusal to File Letter, NurOwn Recipients Call for Advisory Committee Meeting
11/22/2022
Brainstorm Cell Therapeutics is seeking FDA approval of its mesenchymal stem cell therapy called NurOwn for the treatment of ALS.
-
During its third-quarter earnings call Monday, BrainStorm Cell Therapeutics emphasized its commitment to seek an advisory committee meeting for NurOwn in ALS.
-
BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update
11/14/2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update.
-
BrainStorm Cell Therapeutics ran into another stumbling block with ALS hopeful NurOwn Thursday as the FDA issued a Refusal to File Letter for its Biologics License Application.
-
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
11/10/2022
BrainStorm Cell Therapeutics Inc. today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the company's New Biologics License Application (BLA) for NurOwn for the treatment of ALS.
-
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate Update
11/7/2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that it will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on Monday, November 14, 2022.
-
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting
11/7/2022
BrainStorm Cell Therapeutics Inc. announced the presentation of a poster with new analyses from NurOwn's placebo-controlled Phase 3 amyotrophic lateral sclerosis trial that account for limitations in the Revised ALS Functional Rating Scale and provide evidence of a clinically meaningful treatment effect.
-
BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS Congress
10/20/2022
BrainStorm Cell Therapeutics Inc. announced that a scientific abstract titled 'NurOwn Phase 2 Clinical Trial in Progressive MS: Effects on CSF Neuroprotective Biomarkers' will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, being held from October 26-28th in Amsterdam, NL.
-
With military precision and academic ingenuity, Israel is building a thriving biotech ecosystem. Venture capitalists would do well to pay attention.
-
BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research Symposium
10/7/2022
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the presentation of new biomarker analyses supporting the therapeutic benefit of NurOwn® in amyotrophic lateral sclerosis (ALS) at the ongoing 5th Annual ALS ONE Research Symposium.
-
BrainStorm Cell Therapeutics announced the publication of peer-reviewed data from a Phase II trial in progressive multiple sclerosis Thursday showing “preliminary evidence of efficacy.”
-
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
9/15/2022
BrainStorm Cell Therapeutics Inc. announced the peer reviewed publication of data from the Phase 2 trial of NurOwn in progressive multiple sclerosis in Multiple Sclerosis Journal.
-
There are several approaches on the horizon in ALS, a space that is gaining momentum. BioSpace spoke with GeNeuro, NeuroSense and the Tisch MS Research Center about their progress.